Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million.
Atreca is a biopharmaceutical company utilizing a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.
The Davis Polk corporate team included partner Emily Roberts and associates Benson Richards and Sarah Kirk. Partner Frank J. Azzopardi, counsel Daniel F. Forester and associate Daniel P. Kearney provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.